What question did this study set out to answer?

To assess whether teplizumab preserves beta-cell function in individuals with stage 2 type 1 diabetes secondary to autoimmune polyendocrine syndrome 1 (APS-1).

November 12, 2025Diabetes CareOpen Access

Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1

View Full Paper

Ask AI

Bookmark

To assess whether teplizumab preserves beta-cell function in individuals with stage 2 type 1 diabetes secondary to autoimmune polyendocrine syndrome 1 (APS-1).
Administered the anti-CD3 monoclonal antibody teplizumab to two individuals with autoimmune polyendocrine syndrome 1 (APS-1) and stage 2 type 1 diabetes.
Monitored beta-cell preservation and evaluated the need for subsequent immunological and clinical follow-up.
Teplizumab treatment was associated with qualitative preservation of beta-cell function in both individuals with APS-1-related type 1 diabetes.
Durability, efficacy, and underlying tissue and immunologic mechanisms were not quantified and require larger prospective studies.

Implication

Case series demonstrates beta-cell preservation with teplizumab in autoimmune polyendocrine syndrome 1, suggesting potential disease modulation.

Abstract

Teplizumab may preserve β-cell function in APS-1-associated T1D. Larger studies are needed to define efficacy, durability, and immunologic and tissue mechanisms in this rare context.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wilson et al. (2025) studied this question.

synapsesocial.com/papers/69dd4ec899c691022d99c0cb https://doi.org/10.2337/dc25-1444

View Full Paper

Ask AI

Bookmark

Implication

Case series demonstrates beta-cell preservation with teplizumab in autoimmune polyendocrine syndrome 1, suggesting potential disease modulation.

Abstract

Teplizumab may preserve β-cell function in APS-1-associated T1D. Larger studies are needed to define efficacy, durability, and immunologic and tissue mechanisms in this rare context.

Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1

Key Points

Implication

Abstract

Discussion

Cite This Study

Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading